Neurol. praxi. 2018;19(3):161-171 | DOI: 10.36290/neu.2018.003

Diabetic polyneuropathy

MUDr. Gabriel Hajaš, PhD.
Neurogická klinika FSVaZ UKF a FN Nitra

Diabetes causes a broad sprectrum of neuropathic complications, including acute and chronic forms affecting each level of theperipheral nerve, from the root to the distal axon. Diabetic neuropathy (DN) is currently considered a heterogeneous disease withdifferent pathogenetic mechanisms in different clinical syndromes. The most common form is distal symmetric polyneuropathy(DSPN), which often goes insidious and unnoticed and its most serious complication is diabetic foot. In addition to knownrisk factors such as diabetes duration or long-term metabolic control, new factors such as cardiovascular factors (hypertension,hyperlipidemia, obesity), age, smoking, and recurrent episodes of ketoacidosis have recently been identified. In preventing thedevelopment of neuropathy, metabolic control, lifestyle modification and exercise are very important. Among the pathogeneticdrugs, alphalipoic acid has a dominant position. Neuropathic pain treatment is particularly needed to improve the overall patient´s quality of life. Early diagnosis of diabetic neuropathy is crucial for early medical intervention.

Keywords: diabetes, diabetic neuropathy, polyneuropathy, diagnosis, risk factors, treatment

Received: January 7, 2018; Accepted: January 7, 2018; Published: July 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hajaš G. Diabetic polyneuropathy. Neurol. praxi. 2018;19(3):161-171. doi: 10.36290/neu.2018.003.
Download citation

References

  1. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA. DCCT Trial The Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the diabetes control and complications trial (DCCT) on peripheral neuropathy in type 1 diabetes during the epidemiology of diabetes interventions and complications (EDIC) study. Diab Care 2010; 33: 1090-1096. Go to original source... Go to PubMed...
  2. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17: 1113-1123. Go to original source... Go to PubMed...
  3. Bednařík J, Ambler Z. Léčba diabetické neuropatie. Neurol. praxi 2012; 13(Suppl. E): 25-30.
  4. Bednařík J, Ambler Z, Opavský J, Keller O, Rokyta R, Mazanec R, Lejčko J, Kozák J, Suchý M, Pátá M, Kožený P. Klinický standard pro farmakoterapii neuropatické bolesti. Cesk Slov Neurol N 2012; 75/108(1): 93-101.
  5. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D. Evidence-based guideline: treatment of painful diabetic neuropathy. Muscle Nerve 2011; 6: 910-917. Go to original source... Go to PubMed...
  6. Callaghan BC, Cheng H, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012; 11(6): 521-534. Go to original source... Go to PubMed...
  7. Centers for Disease Control and Prevention (CDC). The National Diabetes Statistics Report, 2017.
  8. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004; 21(9): 976-982. Go to original source... Go to PubMed...
  9. Dyck PJ. Detection, characterisation and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1998; 11: 21-32. Go to original source... Go to PubMed...
  10. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ 3rd, O'Brien PC. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999; 22(9): 1479-1486. Go to original source... Go to PubMed...
  11. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM. The Rochester Diabetic Neuropathy Study. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population based cohort. Neurology 1993; 43: 817-824 Go to original source... Go to PubMed...
  12. Dyck JP, Thomas PK. Diabetic neuropathy, 2nd edition. Philadelphia, W.B. Saunders 1999.
  13. Ehler E, Latta J. Bolestivá diabetická neuropatie - léčba založená na důkazech. Neurol. Praxi 2012; 13(5): 269-273.
  14. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393. Go to original source... Go to PubMed...
  15. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000; 47(2): 123-128. Go to original source... Go to PubMed...
  16. Greene DA, Sima AAF, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992; 15(12): 1902-1925. Go to original source... Go to PubMed...
  17. Grofik M, Nosáľ V, Kurča E, Kučera P. Neurologické prejavy diabetes mellitus. Neurol. praxi 2005; 6(1): 28-33.
  18. Hajaš G, Jakubička J. Diabetic neuropathy in children and adolescents - a prospective 5-year study. Cesk Slov Neurol N 2010; 73/106(1): 51-56.
  19. Hajas G, Kissova V, Tirpakova A. A 10-yr follow-up study for the detection of peripheral neuropathy in young patients with type 1 diabetes. Pediatr Diabetes 2016; 17(8): 632-641. Go to original source... Go to PubMed...
  20. Halbichová D. Diabetická neuropatie: nové zkušenosti a poznatky v léčbě. Neurol. praxi 2011; 12(6): 406-410.
  21. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y. Long-term clinical effects of epalrestat, an aldose reduktase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reduktase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006; Jul 29(7): 1538-1544. Go to original source... Go to PubMed...
  22. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM. ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419-430. Go to original source... Go to PubMed...
  23. Juster-Switlyk K, Smith AG. Updates in diabetic peripheral neuropathy. F1000Research. 2016; 5: F1000 Faculty Rev-738. Go to original source... Go to PubMed...
  24. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes prevention program research group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403. Go to original source... Go to PubMed...
  25. Leyden E. Beitrag zur klinik des diabetes mellitus. Wien Med Wochenschrift. 1893; 43: 926.
  26. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol 2012; Article ID 456279: 1-8. Go to original source... Go to PubMed...
  27. Národné centrum zdravotníckych informácií. Ročný výkaz o činnosti diabetologických ambulancií (2000-2014).
  28. Národné centrum zdravotníckych informácií. Zdravotnícka ročenka Slovenskej republiky 2015.
  29. NICE Neuropathic Pain Clinical Guidelines. Available at www. nice. org. uk/guidance/CG96. Last accessed date March 16, 2011.
  30. Ogle JW. On disease of the brain as a result of diabetes mellitus. St George's Hosp. Rep. 1866; 1: 157.
  31. Pavy FW. Introductory address to the discussion of the clinical aspect of glycosuria. Lancet 1885; 126(3250). Go to original source...
  32. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic neuropathy: a Position statement by the American Diabetes Association. Diabetes Care 2017; 40: 136-154. Go to original source... Go to PubMed...
  33. Singleton JR, Marcus RL, Jackson JE, K Lessard M, Graham TE, Smith AG. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol 2014; 1: 844-849. Go to original source... Go to PubMed...
  34. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006; 29: 1294-1299. Go to original source... Go to PubMed...
  35. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfothiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008; 116: 600-605. Go to original source... Go to PubMed...
  36. Tesfaye S. Diabetic neuropathy. In Wass JAH, et al. Oxford Textbook of Endocrinology and Diabetes 2002: 1789-1798.
  37. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity and treatments. Diabetes Care 2010; 33: 2285-2293. Go to original source... Go to PubMed...
  38. Tesfaye S, Chaturvedi N, Simon EM, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C. for the EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350. Go to original source... Go to PubMed...
  39. Tesfaye D. Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012; 28(Suppl. 1): 8-14. Go to original source... Go to PubMed...
  40. Tesfaye D, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD and the EURODIAB IDDM Study Group. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996; 39: 1377-1384. Go to original source... Go to PubMed...
  41. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. Go to original source... Go to PubMed...
  42. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122(8): 561-568. Go to original source... Go to PubMed...
  43. Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009; 58(10): 2376-2385. Go to original source... Go to PubMed...
  44. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000; 43: 957-973. Go to original source... Go to PubMed...
  45. Vlčková-Moravcová E, Bednařík J, Dušek L, Toyka KV, Sommer C. Diagnostic validity of epidermal nerve fiber densities in painful sensory neuropathies. Muscle Nerve 2008; 7: 50-60. Go to original source... Go to PubMed...
  46. Vondrová H. Diagnostika a diferenciální diagnostika diabetické polyneuropatie. Neurol. Praxi 2010; 11(1): 43-46.
  47. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diab Care 2006; 29: 2365-2370. Go to original source... Go to PubMed...
  48. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, Kerum G, Malessa R. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). ALADIN III study group. Alpha-lipoic acid in diabetic neuropathy. Diab Care 1999; 22: 1296-1301. Go to original source... Go to PubMed...
  49. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31(3): 464-469. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.